Cagrilintide

Overview

Cagrilintide is a long-acting amylin receptor agonist. It imitates amylin, a hormone the pancreas releases, to drive a sense of fullness and slow gastric emptying. The main research focus is weight management, and it is often combined with GLP-1 receptor agonists to layer two appetite-suppressing mechanisms and improve blood-sugar control at the same time. Like other peptides, it is generally a research chemical that requires reconstitution and subcutaneous injection, with purity and storage being important.

What the Research Shows

The evidence here is unusually solid for a peptide marketed this way. A phase 2 trial found that once-weekly cagrilintide produced significant, dose-dependent weight loss versus placebo and was generally well tolerated at doses up to 4.5 mg. A review describes its mechanism as a non-selective amylin receptor agonist that cuts food intake and body weight through both central and peripheral routes. A systematic review and meta-analysis of CagriSema, the cagrilintide-plus-semaglutide combination, concluded that the combination outperforms either drug used alone. That said, this is still a drug in development, not an approved standalone product.

Community Sentiment

Across 54 community reports, sentiment is 56% positive, 28% neutral, and 16% negative. The benefits people mention most are weight loss, appetite suppression, and reduced 'food noise.' The downsides cited most often are nausea, fatigue, and bloating, in line with what you would expect from this drug class.

Dosage

Clinical protocols typically open at 0.3 mg once weekly for the first four weeks to check tolerability, then step up roughly every four weeks (0.6 mg, 1.2 mg, 1.8 mg) toward a 2.4 mg maintenance dose. In the CagriSema stack, users often settle around 1.2 mg to 2.4 mg of cagrilintide alongside their GLP-1. Phase 2 trials went as high as 4.5 mg, but most user conversation centers on the 2.4 mg weekly ceiling.

Effectiveness

Clinical data and user reports suggest that, at higher doses, it beats liraglutide 3.0 mg for weight loss. It is frequently recommended for people who have stalled on tirzepatide or semaglutide, and its effect scales clearly with dose, increasing from 0.3 mg up through the 2.4-4.5 mg range.

Availability

Cagrilintide is in late-stage phase 3 trials, often as part of the CagriSema combination, and is not yet FDA-approved as a standalone prescription. Despite that, peptide communities discuss it widely as a research chemical available through specialized lab suppliers, which carries the usual purity and legality concerns.

Bottom Line

The human evidence for cagrilintide is genuinely strong relative to most compounds in this space, with multiple RCTs and meta-analyses behind it. The main caveats are that it has not cleared full approval as a standalone agent, gastrointestinal side effects are common during escalation, and gray-market 'research chemical' sourcing means you cannot verify what you are actually injecting.